E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Obstructive Pulmonary Disease |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10009033 |
E.1.2 | Term | Chronic obstructive pulmonary disease |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The change from baseline in pre-bronchodilator FEV1 at Week 16 |
|
E.2.2 | Secondary objectives of the trial |
• Baseline change in post-bronchodilator FEV1 at Wk16
• Baseline change from baseline in weekly average number of occasions in a day that rescue medication is used at Wk16
• Baseline change in E-RS at Wk16
• Baseline change in total score of the SGRQ-C at Wk16.
• Baseline change in 1' and major 2' endpoints at all visits, up to 24wks
• Baseline change in other spirometry assessments (PEFR, pre- and post-BD FVC, FEF25-75%, FEV1/FVC ratio) up to 24wks
• Baseline change in weekly average daytime/night-time symptoms, and weekly average number of occasions in a day that rescue medication is used, up to 24wks
• Baseline change in weekly average daytime/night-time domiciliary peak flow measurements, up to 24wks
• Number and time to, protocol defined moderate or severe COPD exacerbations, up to 24wks
• Number, intensity and duration of COPD exacerbation events as reported through EXACT PRO, up to 24wks
• PGIC and proportion of patients in each response category, up to 24wks |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Be male or female and ≥40 years and ≤75 years of age.
• Have moderate to severe chronic obstructive pulmonary disease (COPD, Grade II or Grade III according to the GOLD Guidelines
• Have persistent COPD symptoms that required repeated (>1) ‘as needed’ use of a short-acting rescue medication within 4 weeks prior to Study Visit 1.
• Have a diagnosis of chronic bronchitis (defined as sputum production on most days for at least 12 weeks per year for at least 2 successive years) reported by the subject at Study Visit 1.
• Be able to meet at least 1 of the following 2 criteria: have had at least 2 COPD exacerbations requiring antibiotics and/or systemic corticosteroids in the past 2 years; or be able to spontaneously produce an adequate sputum sample at Study Visit 1 or Study Visit 2.
• Be a current or ex-smoker who has a smoking history of at least 10 pack years (10 pack years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.) at Study Visit 1.
• Have been treated with stable dose of LABA and/or long-acting anticholinergic bronchodilators alone or in combination with ICS for at least 4 weeks prior to Study Visit 1.
• Have a percent-predicted post-BD FEV1 ≥40% and <80%, and a post BD FEV1/FVC <0.70 at Visit 1.
• Have a post-BD FEV1 >500 mL at Study Visit 1. Participants in the bronchoscopy substudy must have a post-BD FEV1 >800 mL at Study Visit 1 and Study Visit 2
• No active, old, or latent tuberculosis (TB), and no close contact with active TB patients within 3 months prior to Study visit 1.
|
|
E.4 | Principal exclusion criteria |
• Has a body mass index (BMI) >32.0 kg/m2.
• Has another pulmonary disease, eg, asthma, clinically significant bronchiectasis, cystic fibrosis, sarcoidosis, interstitial lung disorder, moderate or severe sleep apnea, or pulmonary hypertension at Study Visit 1.
• Has a history of granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to Study Visit 1.
• Has ever experienced life-threatening COPD (eg, intensive care unit [ICU] admission, intubation, non-invasive ventilation).
• Has had a lung lobectomy, lung cancer surgery, lung volume reduction, or a lung transplant.
• Has had any of the following respiratory tract conditions within the specified time intervals: pneumonia (as confirmed by chest x-ray findings and treated with antibiotics) within 1 year prior to Study Visit 1; COPD exacerbation that required systemic steroids and/or antibiotics or required hospitalization and was not associated with pneumonia within 6 weeks prior to Study Visit 1; upper or lower respiratory tract infection (including common cold or sinusitis) that was not associated with either pneumonia or COPD exacerbation within 4 weeks prior to Study Visit 1.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The change from baseline in pre-bronchodilator FEV1 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1.Change from baseline in post-bronchodilator FEV1 2.Transitional Dyspnea Index focal score
3.Change from baseline in rescue medication usage 4.Change from baseline in EXACT-RS
5.Change from baseline in total score of the SGRQ-C
6.Changes from baseline in primary endpoint and major secondary endpoints at all visits
7.Change from baseline in other spirometry assessments as measured in the clinic (pre- and post-BD peak expiratory flow rate (PEFR), pre- and post-BD FVC, forced expiratory flow at 25% and 75% of vital capacity (FEF25-75%), FEV1/FVC ratio
8.Change from baseline in weekly average of daytime and night-time symptoms, and weekly average rescue medication usage
9.Change from baseline in weekly average of daytime and night-time domiciliary peak flow measurements
10.Number of investigator-reported COPD exacerbations and time to first exacerbation
11.Number, intensity and duration of COPD exacerbation events as reported through EXACT PRO
12.Patient’s Global Impression of Change (PGIC) and proportion of patients in each response category |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. At Week 16
2. At Week 16
3. At Week 16
4. At Week 16
5. At Week 16
6. Up to 24 weeks
7. Up to 24 weeks
8. Up to 24 weeks
9. Up to 24 weeks
10. Up to 24 weeks
11. Up to 24 weeks
12. Up to 24 weeks
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 44 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
China |
Czech Republic |
Germany |
Hungary |
Korea, Republic of |
Malaysia |
Russian Federation |
Taiwan |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |